Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
301-320 of 653 trials

Narcolepsy: Safety Study of Lu AH69593

We are testing a new medication to see how safe it is for healthy adults and those with narcolepsy. This study will help us understand how well the medication is tolerated.

Narcolepsy1-2 yearsSafety phase (I)Internal MedicineNeurology

Denosumab for Fibrous Dysplasia and McCune-Albright Syndrome

We are studying whether Denosumab can help reduce pain and improve quality of life for adults with Fibrous Dysplasia and McCune-Albright Syndrome. The trial will also look at its effects on mobility and bone health.

Fibrous Dysplasia/McCune-Albright Syndrome1-2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementEndocrinologyOrthopedics and Traumatology

Chronic Myelomonocytic Leukemia: New Treatment Combination Study

We are testing a combination of azacitidine, venetoclax, and tagraxofusp for patients with higher-risk chronic myelomonocytic leukemia. The study aims to evaluate how well this treatment works and its safety.

Chronic Myelomonocytic Leukemia1-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesHematologyOncology

Parkinson’s Disease: RO7568282 Safety Study

We are testing a new drug, RO7568282, to see if it is safe for healthy people and those with Parkinson’s disease. This study will help us understand its effects on the body.

Parkinson's Disease1-2 yearsSafety phase (I)Neurology

Triple Negative Breast Cancer: Imatinib Study

We are investigating whether Imatinib can convert triple negative breast cancer into a more treatable ER-positive type. The study also examines the safety of the drug and its effects on related cancer markers.

Triple Negative Breast CancerPrimary Breast Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncology

Myotonic Dystrophy: Long-Term Study of Mexiletine PR

We are examining the long-term safety and effectiveness of mexiletine PR for treating myotonia in patients with myotonic dystrophy types 1 and 2. This study is for those who have completed a prior related study.

Myotonic Dystrophy1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurology

Hearing Loss in Children: DB-OTO Gene Therapy

We are testing a new gene therapy for children and infants with hearing loss due to specific genetic mutations. The study aims to see if it is safe and effective in improving their hearing and speech skills.

Congenital Hearing Loss1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesOtolaryngologyPediatrics

Immunological Diseases: RAY121 Treatment

We are testing RAY121 for people with various immunological diseases to see if it can help manage their condition by inhibiting the immune response.

Bullous PemphigoidImmune-Mediated Necrotizing MyopathyDermatomyositis1-2 yearsSafety phase (I)DermatologyRheumatology

Hidradenitis Suppurativa: Sonelokimab Treatment Study

We are testing a new injectable medication, sonelokimab, for adults with moderate to severe hidradenitis suppurativa. The study aims to see if it can improve symptoms compared to a placebo.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementAllergologyDermatology

Ulcerative Colitis: Filgotinib for Kids and Teens

We are studying the effects of filgotinib in children and teenagers with moderately to severely active ulcerative colitis. The trial aims to see if it helps achieve remission and improves quality of life.

Ulcerative Colitis1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Crohn's Disease in Children: Mirikizumab Study

We are studying whether Mirikizumab can help children with moderately to severely active Crohn's Disease achieve better health compared to a placebo. This research aims to improve treatment options for young patients.

Crohn's Disease1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

dTap Booster Vaccination for Health Care Workers

We are studying the immune response of health care workers to a dTap booster vaccine for pertussis, diphtheria, and tetanus. This helps us understand how well the vaccine boosts their immunity.

Diphtheria, Tetanus, and Pertussis Immunization1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Chronic Myeloid Leukemia: Olverembatinib Study

We are testing a new drug, Olverembatinib, for patients with Chronic Phase Chronic Myeloid Leukemia. The study aims to see if it works better than the current treatment, Bosutinib, especially for those with a specific mutation.

Chronic Myeloid Leukemia1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Alcohol-Related Liver Disease: GSK4532990 Study

We are investigating a new medication, GSK4532990, for adults with alcohol-related liver disease. The study aims to see if it is safe and effective compared to a placebo.

Alcoholic Liver Disease1-2 yearsEfficacy phase (II)11-15 visitsHepatologyInternal Medicine

Bronchiectasis: 7% Hypertonic Saline Inhalation

We are studying whether inhaling a 7% hypertonic saline solution before physiotherapy helps patients with bronchiectasis clear mucus more effectively. We’ll also look at its impact on cough, quality of life, and any side effects.

Bronchiectasis1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboInvestigational MedicinesInternal MedicinePulmonology

High Blood Pressure: Irbesartan and Amlodipine Combination

We are testing a new fixed-dose pill combining irbesartan and amlodipine for patients with high blood pressure. The goal is to see if it effectively lowers blood pressure and is safe for use.

High Blood Pressure1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Kidney Disease: Frexalimab, Brivekimig, and Rilzabrutinib Study

We are testing three new medications for people aged 16 to 75 with primary focal segmental glomerulosclerosis or minimal change disease. The goal is to see if they can reduce protein in urine and improve kidney function compared to a placebo.

Focal Segmental Glomerulosclerosis (FSGS)Minimal Change Disease (MCD)Immune System Diseases1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicineNephrology

Type 1 Diabetes: Study of NNC0363-1063

We are researching a new medicine to see how it affects healthy participants and those with type 1 diabetes. This study aims to gather information that could improve diabetes treatment.

Type 1 Diabetes1-2 yearsSafety phase (I)DiabetologyEndocrinology

Crohn's Disease: Stem Cell Treatment Study

We are exploring the use of fat-derived stem cells to treat fistulas in people with Crohn's disease. The goal is to find the best dose that may help improve healing.

Crohn’s Fistula1-2 yearsSafety phase (I)Efficacy phase (II)GastroenterologyInternal Medicine

Tremelimumab Injection for Early-Stage Lung Cancer

We are studying a new injection method for delivering tremelimumab to patients with early-stage non-small cell lung cancer. The goal is to evaluate its safety and how well it works in the body.

Non-small cell lung cancer1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology